Sunday 20 November 2016

PharmaPoint: Crohns Disease - Canada Drug Forecast and Market Demand Analysis Opportunities to 2022 Research Report

ResearchMoz added Latest Research Report titled " PharmaPoint: Crohns Disease - Canada Drug Forecast and Market Analysis to 2022 " to it's Large Report database.

The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospiras Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=191948

Based on GlobalDatas primary research survey, the majority of Canadian gastroenterologists follow the AGA guidelines for the management of their CD patients. Over 65% of referrals for CD patients to a gastroenterologist come from PCPs or colorectal surgeons. The peak age for the diagnosis of CD in over 65% of cases in Canada is 1740 years, and the diagnosis is typically confirmed by clinical evaluation and a combination of hematological, endoscopic, histological, or imaging-based investigations following the initial presenting symptoms of abdominal pain, diarrhea, and weight loss, or the more common systemic symptoms of malaise, anorexia, and fever.

Scope
  • Overview of Crohns disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Canada from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Canada Crohns disease market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 18
3.3 Prognosis 19
3.4 Quality of Life 19

4 Disease Management 20
4.1 Treatment Overview 21
4.2 Canada 26
4.2.1 Diagnosis 26
4.2.2 Clinical Practice 26

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment